What we do

For more than 45 years we’ve been creating high-quality medicines and making them accessible to the people who need them.

Learn more about how we do this across North America, MENA and Europe.

Investors

Together we are building a leading generics and specialty pharmaceutical company where everyone can thrive.

Learn more about our strategy, investment case and track record of success.

Responsibility

Learn more about how we put better health within reach, every day and make a difference to people’s lives.

Careers

We're looking for people who share our passion and want to help us make a real difference in the world.

Newsroom

Featured

Press Release, Product 05 June 2025

Hikma launches Triamcinolone Acetonide Injectable Suspension, USP, in the US Press Release, Product 05 June 2025 Hikma launches Triamcinolone Acetonide Injectable Suspension, USP, in the US
Fitch upgrades Hikma Pharmaceuticals PLC’s long-term issuer default rating to ‘BBB’, outlook stable Press Release, Corporate 29 May 2025 Fitch upgrades Hikma Pharmaceuticals PLC’s long-term issuer default rating to ‘BBB’, outlook stable
Bio-Thera Solutions and Hikma Pharmaceuticals announce FDA approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection Press Release, Product 27 May 2025 Bio-Thera Solutions and Hikma Pharmaceuticals announce FDA approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection
Hikma announces strong medium-term Group guidance ahead of its US site visit Press Release, Corporate 15 May 2025 Hikma announces strong medium-term Group guidance ahead of its US site visit